ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy |
Ozdemir, Ozer
(Department of Chest Diseases, Ege University Faculty of Medicine)
Ozdemir, Pelin (Department of Chest Diseases, Ege University Faculty of Medicine) Veral, Ali (Department of Pathology, Ege University Faculty of Medicine) Uluer, Hatice (Department of Biostatistics, Ege University Faculty of Medicine) Ozhan, Mustafa Hikmet (Department of Chest Diseases, Ege University Faculty of Medicine) |
1 | Bepler G, Gautam A, McIntyre LM, et al (2002). Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol, 20, 1353-60. DOI ScienceOn |
2 | Bepler G, Begum M, Simon GR (2008). Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control, 15, 130-9. |
3 | Bepler G, Williams C, Schell MJ, et al (2013). Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 31, 2404-12. DOI ScienceOn |
4 | Breen D, Barlesi F (2008). The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer. Eur J Cardiothorac Surg, 33, 805-11. DOI ScienceOn |
5 | Ceppi P, Volante M, Novello S, et al (2006). ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 17, 1818-25. DOI ScienceOn |
6 | Chen S, Zhang J, Wang R, Luo X, Chen H (2010). The platinum based treatments for advanced nonsmall cell lung cancer, is low/negative ERCC1 expression beter than high/positive ERCC1 expression? A metaanalysis. Lung Cancer, 70, 63-70. DOI ScienceOn |
7 | Fink D, Zheng H, Nebel S (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res, 57, 1841-5. |
8 | Friboulet L, Olaussen KA, Pignon JP, et al (2013). ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med, 368, 1101-10. DOI ScienceOn |
9 | Gao Z, Han B, Shen J, et al (2011). ERCC1 protein as a guide for individualized chemotherapy of late stage advanced non small cell lung cancer. Exp Ther Med, 2, 811-15. |
10 | Gomez-Roca C, Raynaud CM, Penault-Llorca F, et al (2009). Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol, 4, 1212-20. DOI |
11 | Greene FL, Page DL, Fleming ID, et al (2002). AJCC Cancer Staging Manual. 6th ed. Springer: New York. |
12 | Groome PA, Bolejack V, Crowley JJ, et al (2007). The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 694-705. DOI |
13 | Italiano A, Burel-Vandenbos F, Otto J (2006). Comparison of the epidermal growth factor receptor gene and protein in primary nonsmall-cell lung cancer and metastatic sites: implications for treatment with EGFR inhibitors. Ann Oncol, 17, 981-5. DOI ScienceOn |
14 | Lee HW, Choi YW, Han JH, et al (2009). Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum based doublet chemotherapy. Lung Cancer, 65, 377-82. DOI ScienceOn |
15 | Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91. |
16 | Ludovic C, Gillet J, Scharer OD (2006). Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev, 106, 253-76. DOI ScienceOn |
17 | Rosell R, Taron M, Barnadas A, et al (2003). Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control, 10, 297-305. |
18 | Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: The role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. DOI ScienceOn |
19 | Olaussen KA, Dunant A, Fouret P, et al (2006). DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91. DOI ScienceOn |
20 | Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. DOI ScienceOn |
21 | Roth JA, Carlson JJ (2011). The prognostic role of ERCC1 in advanced non-small cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer, 12, 393-401. DOI ScienceOn |
22 | Sekine I, Minna JD, Nishio K, Tamura T, Saijo N (2006). A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol, 1, 31-7. DOI |
23 | Simon GR, Ismail-Khan R, Bepler G (2007). Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. Int J Biochem & Cell Biology, 39, 1318-28. DOI ScienceOn |
24 | Taillade L, Penault-Llorca F, Boulet T, et al (2007). Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol, 18, 1043-50. DOI ScienceOn |
25 | van Zandwijk N (2001). Neoadjuvant strategies for non-small cell lung cancer. Lung Cancer, 34, 145-50. DOI ScienceOn |
26 | Zheng Z, Chen T, Li X, et al (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 356, 800-8. DOI ScienceOn |